We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience, read our Cookie Policy

RPC' Wholly-Owned Subsidiary NuVax Therapeutics Signs Exclusive License Agreement with University of Florida

News   Jan 27, 2011

 
RPC' Wholly-Owned Subsidiary NuVax Therapeutics Signs Exclusive License Agreement with University of Florida
 
 
 

RELATED ARTICLES

HPV Partners Up with Protein to Form Tumors

News

Researchers have determined that HPV takes the help of a protein present in our cells (USP46) which becomes essential for HPV-induced tumor formation and growth. USP46 could be a promising therapeutic target.

READ MORE

Duchenne Muscular Dystrophy: At-home Monitoring of Lung Function Made Easier

News

Home-based monitoring shows promise as an effective way to boost patient compliance while obtaining reliable clinical information without a hospital visit.

READ MORE

Alzheimer's Trafficking Defect Corrected in Rodents

News

UT Southwestern researchers have succeeded in neutralizing what they believe is a primary factor in late-onset Alzheimer’s disease, opening the door to development of a drug that could be administered before age 40, and taken for life, to potentially prevent the disease in 50 to 80 percent of at-risk adults.

READ MORE

 

Like what you just read? You can find similar content on the communities below.

Drug Discovery Immunology & Microbiology

To personalize the content you see on Technology Networks homepage, Log In or Subscribe for Free

LOGIN SUBSCRIBE FOR FREE